---
title: "Iovance raises FY 2026 total revenue guidance to $410 million-$420 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300424429.md"
description: "Iovance Biotherapeutics raised its full-year 2026 total revenue guidance to $410 million-$420 million, up from the previous $350 million-$370 million range. This midpoint increase of $55 million reflects nearly 60% annual growth, driven by strong U.S. demand for Amtagvi and Proleukin. Second-quarter 2026 product revenue hit a record $99.3 million, and the authorized treatment center network has expanded to approximately 100 centers."
datetime: "2026-09-29T11:02:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300424429.md)
  - [en](https://longbridge.com/en/news/300424429.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300424429.md)
generator: "portal-rs"
---

# Iovance raises FY 2026 total revenue guidance to $410 million-$420 million

-   Iovance Biotherapeutics raised full-year 2026 total revenue guidance to $410 million-$420 million from $350 million-$370 million. \* The midpoint increase is $55 million, about 15%, implying nearly 60% annual growth in total revenue. \* Outlook reflects strong U.S. demand for Amtagvi and Proleukin. \* Second-quarter 2026 total product revenue reached a record $99.3 million. \* Authorized treatment center network expanded to about 100 centers, targeting at least 110 by year-end 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290700PRIMZONEFULLFEED9835587) on September 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)

## Related News & Research

- [Iovance hits highest since 2024 as analysts cheer guidance raise](https://longbridge.com/en/news/300475072.md)
- [Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars](https://longbridge.com/en/news/300468527.md)
- [Iovance Biotherapeutics Names Noah Berkowitz CMO](https://longbridge.com/en/news/300682050.md)
- [Planet Labs director Ita M Brennan disposes of USD 187,478 in common shares](https://longbridge.com/en/news/300831322.md)
- [Roblox Director Gregory Baszucki disposes of USD 358,205 in common shares](https://longbridge.com/en/news/300830750.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**